 |
||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||
|
|
1994
|
||||||||||||||||||||||||||||||||||||||||||||||
| A Population Pharmacokinetic Study Of Alminoprofen Penetration Into Synovial Fluid |
| Population analysis of a dose ranging study |
| Interaction between structural, statistical and covariate models in population pharmacokinetic analysis |
| Three New Residual Error Models For Population PK/PD Analyses |
| Pitfalls in Retrospective Analysis in Search of Concentration-Effect Relationships |
| Population pharmacokinetics of nortriptyline at monotherapy and during concomitant treatment with drugs that inhibit CYP2D6; an evaluation with the nonparametric maximum likelihood method |
| Evaluation Of Bayesian Estimators For Adaptative Control Of Vancomycin Built With Two Methods Of Population Modeling |
| Estimation of Population Pharmacokinetic Parameters of Tobramycin in Intensive Care Unit Patients Using Different Programs |
| Use of the EM algorithm in population pharmacokinetic analysis |
| Comparison of Bayesian Optimal Designs with Respect to Variations of the Population Characteristics. For a Pharmacokinetic and a Pharmacodynamic Model |
| Optimal Sampling Times Determination By Criteria Incorporating Knowledge Of Parameter Distribution In The Population |
| The Use of NONMEM in Interspecies Allometric Scaling |
| Effect of covariatcs on steady-state trough plasma bismuth concentrations from GR122311X in duodenal ulcer patients. |
| A Population Approach to Dose Versus Response Relationship For Simvastatin in Hypertensive Hypercholesterolaemic Patients. |
| Population Pharmacokinetics Of Oral Sumatriptan |
| Pharmacokinetics Of S-12024 By A Prospective Population Approach In Phase II. |
| Caffeine Pharmacokinetics In a Pediatric Population |
| The Population Pharmacokinetics of Ondansetron from Phase 1 Studies |
| Population pharmacokinetics of midazolam in neonates |
| Pharmacokinetics of Meropenem in pediatrics - NONMEM analysis |
| Comparison of Practical Sampling Strategies for Population Pharmacokinetic Studies |
| Population Approaches in Drug Development: Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software |
| Cyclosporine Population Pharmacokinetic Parameters In The Early Postoperative Hepatic Transplantation Phase: Preliminary Results |
| Information Theory in Drug Development. Applications to a new antidepressant. |
| Non-Parametric Density Estimation Applied To Population Studies |
| Stability Of Covariate Models |
| The Nonparametric Maximum Likelihood Method (NPML) |
| POPKAN - Population Pharmacokinetic Analysis using Bayesian Inference |
| P-PHARM: A Population Pharmacokinetic-Pharmacodynamic Data Modeling Software |
| NPEM2: A Nonparametric Program Useful For Clinical Uses : Both Population Pharmacokinetic Modeling, Leading To “Multiple Model” (MM) Adaptive Control |
| Diagnostics For Nonlinear Mixed Effects Models |
| APIS : A software for clinical and experimental pharmacokinetics |
| Covariate Identification for Population Pharmacokinetic Modelling |
| Review of methods |
| The Future Place Of Modeling In Drug Development |
| Implementation of pharmacometric approaches into clinical drug development ? A prospective view |
| Combining Studies : Opportunities And Pitfalls |
| A Validation For A Population Pharmacokinetic Model For Docetaxel |
| Issues and Suggested Solutions in Drug Development |
| Carboplatin Population Pharmacokinetics |
| A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics |
| MicroPharm Population (MP2) - An interactive and user-friendly interfaced program for population pharmacokinetics. |
